Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for SITC and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for SITC and 80,000+ other tickers.
See exactly how SITC's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for SITC and 80,000+ other tickers.
SITE Centers specializes in the ownership and management of open-air retail complexes, curating an engaging shopping atmosphere and a desirable selection of stores for both its retail tenants and their customers. As a self-governing Real Estate Investment Trust (REIT), the company operates as a fully integrated real estate enterprise, managing all aspects of its operations internally. Its shares are publicly available on the New York Stock Exchange under the ticker symbol SITC.
CHICAGO, Oct. 20, 2026 /PRNewswire/ -- Pine Tree, a national owner and operator of open-air shopping centers, announced that it has acquired sponsor interest in a 10-property portfolio recently appraised at $644 million and totaling 3.5 million square feet. The interest was acquired from SITE Centers (NYSE: SITC) in partnership with a large international investor.
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Announces Sale of DTP Interests and Special Common Distribution.
Next generation multispecific technology designed to coordinate innate and adaptive immune activity within the tumor microenvironment SEATTLE, WA / ACCESS Newswire / October 14, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel bispecific and multispecific immunotherapies for the treatment of cancer, today announced that the Company will highlight its multispecific platform in a presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, being held November 4-8, 2026, at the Phoenix Convention Center in Phoenix, Arizona. Aptevo's presentation will feature its broader CD40-directed multispecific portfolio and the Company's approach to bringing together two critical arms of the immune system - innate and adaptive immunity - within the tumor microenvironment.
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), today announced that four abstracts featuring preclinical research from their respective immunotherapy programs have been selected for poster presentations at the Society for Immunotherapy of Cancer (SITC) 41th Anniversary Annual Meeting, taking place November 4-8, 2026, in Phoenix, AZ. The presentations will feature BriaCell's personalized off-the-shelf immunotherapy, Bria-OTS+™ and BriaPro's research on tumor-targeted checkpoint inhibitors, soluble CD80 (BP-80), and engineered CD80 variants.
Site Centers (NYSE: SITC - Get Free Report) and Deutsche Bank Aktiengesellschaft (NYSE: DB - Get Free Report) are both finance companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, earnings, analyst recommendations and dividends. Insider and Institutional Ownership 88.7% of Site